NASDAQ:INM

InMed Pharmaceuticals News Headlines

$1.99
-0.07 (-3.40 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.99
$2.14
50-Day Range
$1.99
$2.96
52-Week Range
$1.93
$8.94
Volume81,693 shs
Average Volume103,253 shs
Market Capitalization$17.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

InMed Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INM
News Sentiment

0.25

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INM Articles
This Week

6

0

INM Articles
Average Week

Get InMed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.

InMed Pharmaceuticals (NASDAQ INM) News Headlines Today

SourceHeadline
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
feeds.benzinga.com - September 17 at 1:38 PM
InMed Pharmaceuticals and BayMedica Participating in Tribe Publics Webinar "Accelerating The Commercialization of Rare Cannabinoids"InMed Pharmaceuticals and BayMedica Participating in Tribe Public's Webinar "Accelerating The Commercialization of Rare Cannabinoids"
benzinga.com - September 17 at 7:55 AM
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
finance.yahoo.com - September 17 at 7:55 AM
InMed Pharmaceuticals to Buy BayMedica in Stock DealInMed Pharmaceuticals to Buy BayMedica in Stock Deal
marketwatch.com - September 14 at 9:06 PM
Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Decreases By 92.4%Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Decreases By 92.4%
americanbankingnews.com - September 14 at 4:36 PM
 Analysts Anticipate InMed Pharmaceuticals Inc. (NASDAQ:INM) Will Announce Earnings of -$0.34 Per Share Analysts Anticipate InMed Pharmaceuticals Inc. (NASDAQ:INM) Will Announce Earnings of -$0.34 Per Share
americanbankingnews.com - September 3 at 1:10 AM
InMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest UpdateInMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest Update
americanbankingnews.com - August 30 at 6:38 PM
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare CannabinoidsInMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
finance.yahoo.com - June 29 at 8:30 AM
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq RulesInMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - June 29 at 8:30 AM
Chronic Obstructive Pulmonary Disease Drugs Market To Rise in the 7MM By 2030, Analysis by DelveInsightChronic Obstructive Pulmonary Disease Drugs Market To Rise in the 7MM By 2030, Analysis by DelveInsight
finanznachrichten.de - June 26 at 8:55 AM
Stock Alert: InMed Pharma Gains 5%Stock Alert: InMed Pharma Gains 5%
markets.businessinsider.com - June 17 at 2:10 PM
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale ProductionInMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
finance.yahoo.com - June 17 at 9:10 AM
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
finance.yahoo.com - May 4 at 7:59 AM
Stocks in play: InMed Pharmaceuticals Inc.Stocks in play: InMed Pharmaceuticals Inc.
ca.finance.yahoo.com - April 29 at 12:23 PM
InMed Pharmaceuticals Announces Voluntary Delisting from TSXInMed Pharmaceuticals Announces Voluntary Delisting from TSX
finance.yahoo.com - April 27 at 8:15 AM
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
finance.yahoo.com - April 26 at 9:19 AM
Edison Investment Research Limited: InMed Pharmaceuticals (INM): Phase II Enrolment to Begin in Second HalfEdison Investment Research Limited: InMed Pharmaceuticals (INM): Phase II Enrolment to Begin in Second Half
finanznachrichten.de - February 23 at 8:12 PM
InMed Pharmaceuticals Inc Registered Shs BuyInMed Pharmaceuticals Inc Registered Shs Buy
markets.businessinsider.com - February 18 at 6:37 PM
InMed Announces Closing of US$4.5 Million Private PlacementInMed Announces Closing of US$4.5 Million Private Placement
finance.yahoo.com - February 16 at 8:09 AM
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial ResultsInMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
finance.yahoo.com - February 11 at 8:49 AM
Edison Investment Research Limited: InMed Pharmaceuticals (INM): INM-755 Phase I Complete, on to Phase IIEdison Investment Research Limited: InMed Pharmaceuticals (INM): INM-755 Phase I Complete, on to Phase II
finanznachrichten.de - January 11 at 9:02 AM
InMed Pharmaceuticals (INM): INM-755 Phase I Complete, on to Phase IIInMed Pharmaceuticals (INM): INM-755 Phase I Complete, on to Phase II
benzinga.com - January 11 at 9:02 AM
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy SubjectsInMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
finance.yahoo.com - January 8 at 7:48 AM
InMed to Participate at Virtual Conferences in January 2021InMed to Participate at Virtual Conferences in January 2021
finance.yahoo.com - January 5 at 5:47 PM
INM.OQ - InMed Pharmaceuticals Inc Profile | ReutersINM.OQ - InMed Pharmaceuticals Inc Profile | Reuters
reuters.com - December 27 at 11:25 PM
Get InMed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.